GH Research price target lowered to $39 from $42 at Citizens

Citizens analyst Jason Butler lowered the firm’s price target on GH Research (GHRS) to $39 from $42 and keeps an Outperform rating on the shares. GH Research reported continued progress with its GH001 program, reaffirmed plans to begin a pivotal Phase 3 trial in late 2026 following ongoing discussions with the FDA, and ended the quarter with approximately $267M in cash, which appears sufficient to fund the global development program, the analyst tells investors in a research note.